The FDA has approved the first blood test to assist in diagnosing Alzheimer's disease for individuals aged 55 and older showing symptoms. This breakthrough, developed by Fujirebio Diagnostics, measures the ratio of two proteins in blood to determine the presence of amyloid plaques, indicative of Alzheimer's. Clinical studies showed high accuracy in confirming diagnosis with a positive rate of over 91%. This test offers a less invasive, more accessible starting point for diagnosis compared to traditional methods, reducing the wait time for patients to get evaluated.
This blood test will allow primary care providers to start the diagnostic process, which is meaningful because patients typically wait months to be evaluated by a neurologist.
Collection
[
|
...
]